Skip to contentP
Perspective Therapeutics, Inc.
P
CATXPerspective Therapeutics, Inc. Q2 2025 · 10-Q
Revenue—
Net Income-$21.49M-$21.49MN/M vs Q2 2024 EPS Diluted-$0.29-$0.29N/M vs Q2 2024 Operating Income-$24,039,000N/M Operating Cash Flowderived-$19,953,000N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Perspective Therapeutics, Inc. · CIK 728387 · Engraved from SEC EDGAR
Free Cash Flowderived-$20,979,000N/M ended Jun 30, 2025 · filed Aug 13, 2025 · 44 d after period end